1943 PROSTATE SPECIFIC ANTIGEN DENSITY VELOCITY ON DUTASTERIDE HELPS PREDICT NEGATIVE PROSTATE BIOPSY: ANALYSIS OF THE REDUCE TRIAL

2013 ◽  
Vol 189 (4S) ◽  
Author(s):  
Michael Maddox ◽  
Joseph Renzulli ◽  
Dragan Golijanin ◽  
Sammy Elsamra ◽  
Matthew Somerville ◽  
...  
Keyword(s):  
Prostate Specific Antigen ◽  
Prostate Biopsy ◽  
Specific Antigen ◽  
Prostate Specific Antigen Density ◽  
Negative Prostate Biopsy

scholarly journals The use of prostate specific antigen density to predict clinically significant prostate cancer

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Igor Yusim ◽  
Muhammad Krenawi ◽  
Elad Mazor ◽  
Victor Novack ◽  
Nicola J. Mabjeesh
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Prostate Biopsy ◽  
Prostate Volume ◽  
Characteristic Curve ◽  
Specific Antigen ◽  
Digital Rectal Examination ◽  
Prostate Adenocarcinoma ◽  
Prostate Specific Antigen Density ◽  
Clinically Significant

AbstractThe purpose of this study was to assess the predictive value of prostate specific antigen density (PSAD) for detection of clinically significant prostate cancer in men undergoing systematic transrectal ultrasound (TRUS)-guided prostate biopsy. We retrospectively analyzed data of men who underwent TRUS-guided prostate biopsy because of elevated PSA (≤ 20 ng/ml) or abnormal digital rectal examination. Receiver operating characteristic curve analysis to compare PSA and PSAD performance and chi-square automatic interaction detector methodologies were used to identify predictors of clinically significant cancer (Gleason score ≥ 7 or international society of urological pathology grade group ≥ 2). Nine-hundred and ninety-two consecutive men with a median age of 66 years (IQR 61–71) were included in the study. Median PSAD was 0.10 ng/ml2 (IQR 0.10–0.22). Prostate adenocarcinoma was diagnosed in 338 men (34%). Clinically significant prostate adenocarcinoma was diagnosed in 167 patients (50% of all cancers and 17% of the whole cohort). The AUC to predict clinically significant prostate cancer was 0.64 for PSA and 0.78 for PSAD (P < 0.001). The highest Youden's index for PSAD was at 0.20 ng/ml2 with 70% sensitivity and 79% specificity for the diagnosis of clinically significant cancer. Men with PSAD < 0.09 ng/ml2 had only 4% chance of having clinically significant disease. The detection rate of clinically significant prostate cancer in patients with PSAD between 0.09 and 0.19 ng/ml2 was significantly higher when prostate volume was less than 33 ml. In conclusion, PSAD was a better predictor than PSA alone of clinically significant prostate cancer in patients undergoing TRUS-guided biopsy. Patients with PSAD below 0.09 ng/ml2 were unlikely to harbor clinically significant prostate cancer. Combining PSAD in the gray zone (0.09–0.19) with prostate volume below 33 ml adds diagnostic value of clinically significant prostate cancer.

scholarly journals Predicting the Diagnosis of Prostate Cancer with a Scoring System Based on Novel Biomarkers

2021 ◽  
Author(s):  
Durvesh Lachman Jethwani ◽  
Lameena Lalitha Sivamoorthy ◽  
Charng Chee Toh ◽  
Rohan Malek
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Prostate Biopsy ◽  
Scoring System ◽  
Univariate Analysis ◽  
Specific Antigen ◽  
Independent Variables ◽  
Prostate Specific Antigen Density ◽  
Novel Biomarkers ◽  
Disease Specificity

Abstract Objective: To predict prostate cancer using novel biomarker ratios and create a predictive scoring system.Materials and Methods: Data of a total of 703 patients who consulted Urology Department of Selayang Hospital between January 2013 and December 2017 and underwent prostate biopsy were screened retrospectively. Prostate specific antigen (PSA) levels, prostate volumes (PV), neutrophil and lymphocyte counts, neutrophil-to-lymphocyte ratio (NLR), Prostate specific antigen density (PSAD)and histopathology were evaluated. Results: Ages ranged from43-89 years, divided into 2 groups as per biopsy results; positive for prostate cancer (n=290, 41.3%) and negative for malignancy (n=413; 58.7%). Intergroup comparative evaluations were performed. Independent variables with p<0.001 in the univariate analysis were age, DRE, PV, NLR, PSAD.A scoring system was modelled using NLR <0.9, PSAD >0.4, Age >70 and DRE. A score of 2 or more predicted prostate cancer with a Sensitivity of 83.8% and Specificityof 86.4%Conclusions: NLR is shown to be good predictor for prostate cancer its usage in this scoring system affords more disease specificity as compared to PSA alone.

Sign in / Sign up

Export Citation Format

Share Document